Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
Agenus (NASDAQ: AGEN), a leader in immuno-oncology, will participate in the 5th Annual Evercore ISI HealthCONx Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus (NASDAQ: AGEN), a leader in immuno-oncology, will participate in the 5th Annual Evercore ISI HealthCONx Conference. Dr. Garo Armen and Dr. Steven O'Day will join a virtual fireside chat on November 30th at 12:35 PM ET. The conference runs from November 29th to December 1st, including one-on-one investor meetings. Interested attendees can register for the webcast, which will also be archived on Agenus' investor website following the event. Agenus focuses on therapies that harness the immune system to combat cancer and infections.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was +2.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 12:35pm ET. The Conference will be held virtually from November 29th – December 1st, during which Agenus will host one-on-one meetings with investors.
Registration for the webcast can be accessed at https://wsw.com/webcast/evercore29/agen/2333250. Following the webcast, an archived version will be available on the Investors section of the Agenus website at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Inc.
Nico Frelick
Investor Relations
781-674-4616
Nico.frelick@agenusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.